Gynecologic Oncology

Papers
(The H4-Index of Gynecologic Oncology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer203
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery90
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA12586
Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)85
Patient-reported post-discharge opioid use after abdominal gynecologic surgery in an Enhanced Recovery After Surgery (ERAS) program (004)80
Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)76
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes73
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials73
Redefining readmissions in gynecologic cancer: readmissions resulting in hospital-to-hospice transitions may represent high value care72
Sentinel lymph node procedures in endometrial cancer: an international multicenter experience70
Stage IV gynecologic cancers patients who subsequently died from disease: lessons learned from their health care journey63
The impact of the SARS-COV2 pandemic on the delivery of chemotherapy for gynecologic cancer at a tertiary care institution in the United States epicenter61
Taking the ‘first steps’ to a healthier lifestyle: The initial acceptability and feasibility of a health behavior intervention for endometrial cancer survivors with obesity and their social support ne56
Outcomes of splenectomy during primary cytoreductive surgery in ovarian cancer53
Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)53
Neoadjuvant chemotherapy with interval debulking surgery versus chemotherapy alone for advanced epithelial ovarian cancer52
Predictors of long-term response in prospective phase II trial of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer (1247)51
Recurrent ovarian cancer: maintenance treatment with PARP inhibitors in clinical practice51
Prognostic factors of survival in women with recurrent platinum-resistant epithelial ovarian cancer (1171)51
Perioperative outcomes in obese women with uterine cancer51
Short-term hormone replacement therapy in BRCA mutation carriers and risk of breast cancer: A nationwide study in Korea (1155)51
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 120350
TOGETHER Care: PatienT-tailOred GynEcologic Oncology posT discHargE caRe (290)48
Hot or not: defining trophoblast PD-L1 expression and lymphohistiocytic density in gestational trophoblastic neoplasia47
Impact of surgeon type and rurality on treatment and survival of ovarian cancer patients46
Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery: a National Surgical Quality Improvement Program analysis (467)45
Diversifying clinical trials: Does presentation at gynecologic oncology tumor board increase equitable access to clinical trials for Black and LatinX patients? (2205)44
Clinical impact of low-volume lymph node metastases in early- stage cervical cancer: A comprehensive meta-analysis (504)43
Clinical outcomes and cost associated with HRD biomarker guided first line maintenance therapy in advanced ovarian cancer43
Determining the optimal adjuvant therapy strategy in uterine leiomyosarcoma43
Comparison of solid tumor mutations under the targeted agent and profiling utilization registry (TAPUR) study: how do gynecologic cancers compare with others?42
Improving the cancer survivorship journey: Developing a survivorship care transition model for rural and underserved low risk breast and gynecologic cancer patients (511)41
Role of lymphadenectomy for apparent early-stage low-grade serous ovarian carcinoma (529)41
Mitigating disparity? Recurrence rates and palliative care referrals by race and ethnicity across a large urban health system (514)41
Disparities in access to high volume surgeons within high volume hospitals for hysterectomy41
Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer40
Impact of increased cycles of neoadjuvant chemotherapy on interval debulking surgery outcomes (541)40
The impact of bowel preparation on surgical site infection rates in gynecologic oncology surgery, post-hoc analysis from a randomized controlled trial (550)39
Pattern of recurrence and survival: Comparative analysis of robotic radical hysterectomy with uterine manipulator versus without uterine manipulator and or vaginal cerclage in treatment of stage IB ce39
0.17744708061218